Study #2023-0783
Phase 3, multicenter, randomized, open-label study evaluating efficacy of sotorasib platinum doublet combination versus pembrolizumab platinum doublet combination as a front-line therapy in subjects with stage IV or advanced stage IIIB/C nonsquamous non-small cell lung cancers, negative for PD-L1, and positive for KRAS p.G12C (CodeBreaK 202)
MD Anderson Study Status
Enrolling
Treatment Agent
Sotorasib, Pembrolizumab
Description
The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-Small Cell Lung Cancer (NSCLC)
Study phase:
Phase III
Physician name:
Ferdinandos Skoulidis
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-491-2084
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.